Test Your Understanding Quiz 4

Prev
 1 / 17 
Next
Prev
 1 / 17 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • Distinguish therapies that target complement activation from those that target the underlying B-cell clone
  • Select treatment strategies based on the dominant mechanism of disease activity
  • Recognize the strengths and limitations of different therapeutic approaches in CAD
  • Identify clinical scenarios in which complement inhibition, clone-directed therapy, or both may be appropriate

A patient with CAD develops worsening anemia with hemoglobin 7.2 g/dL and laboratory evidence of active hemolysis.

Which treatment strategy most directly targets the mechanism responsible for the anemia?

a
Rituximab therapy
Rituximab targets the B-cell clone producing IgM antibodies but does not immediately stop complement-mediated hemolysis.
b
Complement inhibition therapy
Complement inhibitors such as sutimlimab block activation of the classical complement pathway (C1s), rapidly reducing RBC destruction.
c
Thermal protection measures
Thermal protection helps prevent cold-triggered agglutination but does not directly treat hemolysis.
d
Iron supplementation
Iron supplementation does not address immune-mediated RBC destruction.

Which statement best describes the therapeutic goal of clone-directed therapy in primary CAD?

a
Prevent complement activation on RBCs
Preventing complement activation is the goal of complement inhibitors.
b
Eliminate or suppress the B-cell clone producing pathogenic IgM antibodies
Clone-directed therapy targets the underlying IgM-producing B-cell clone, often using rituximab-based regimens.
c
Increase erythropoiesis
Increasing erythropoiesis does not address the immune mechanism of CAD.
d
Reduce RBC agglutination in peripheral vessels
Agglutination results from antibody binding rather than RBC production.

Which characteristic best distinguishes complement inhibition therapy from clone-directed therapy?

a
Complement inhibitors eliminate the pathogenic B-cell clone
Complement inhibitors do not eliminate the B-cell clone.
b
Complement inhibitors rapidly reduce hemolysis without eliminating antibody production
Complement inhibitors interrupt complement activation and therefore reduce hemolysis within days, but they do not reduce IgM antibody production.
c
Clone-directed therapy works immediately to stop hemolysis
Clone-directed therapy may require weeks to months before antibody levels fall.
d
Clone-directed therapy prevents RBC agglutination
Clone-directed therapy does not directly prevent RBC agglutination.

Which clinical situation most strongly favors complement inhibition therapy rather than clone-directed therapy?

a
Severe hemolytic anemia requiring rapid control
Complement inhibitors can rapidly control hemolysis and are appropriate when immediate improvement in hemoglobin is required.
b
Mild seasonal acrocyanosis without anemia
Mild circulatory symptoms are usually managed with supportive measures.
c
Incidental cold agglutinins without hemolysis
Incidental cold agglutinins without hemolysis do not require therapy.
d
Stable anemia without symptoms
Stable asymptomatic anemia often does not require treatment.

Which therapy is most likely to produce durable reduction in IgM antibody production?

a
Complement inhibition therapy
Complement inhibition suppresses hemolysis but requires ongoing therapy.
b
Clone-directed B-cell therapy
Clone-directed therapies such as rituximab or bendamustine–rituximab target the pathogenic B-cell clone and may produce durable responses.
c
Thermal protection
Thermal protection reduces symptoms but does not alter antibody production.
d
Blood transfusion
Transfusion temporarily replaces RBCs.

Why does complement inhibition therapy often improve anemia quickly but have limited effect on circulatory symptoms?

a
Complement inhibition increases erythropoiesis
Complement inhibitors do not increase erythropoiesis.
b
Circulatory symptoms result from iron deficiency
Circulatory symptoms are unrelated to iron deficiency.
c
Complement inhibitors increase IgM antibody production
Complement inhibitors do not increase antibody production.
d
Circulatory symptoms are caused by RBC agglutination rather than hemolysis
Circulatory symptoms arise from IgM-mediated RBC agglutination in cooled peripheral vessels, which is not directly affected by complement inhibition.

A patient with CAD has persistent hemolysis despite strict thermal protection.

Which therapeutic strategy most directly addresses the remaining mechanism?

a
Complement inhibition therapy
Complement inhibition blocks complement-mediated RBC destruction responsible for hemolysis.
b
Iron supplementation
Iron supplementation does not address immune hemolysis.
c
Splenectomy
Splenectomy is ineffective because hemolysis occurs primarily in the liver.
d
Erythropoietin therapy
Erythropoietin does not treat immune-mediated hemolysis.

Which statement best describes the relationship between complement inhibition and clone-directed therapy?

a
They target different levels of the disease mechanism
Complement inhibition targets the downstream effector pathway, while clone-directed therapy targets the upstream source of antibody production. In some patients, both approaches may be used sequentially or together.
b
Both eliminate the pathogenic antibody
Complement inhibitors do not eliminate the antibody.
c
Both immediately stop hemolysis
Clone-directed therapy does not act immediately.
d
Both prevent RBC agglutination
Neither therapy directly prevents RBC agglutination.

Which patient scenario most strongly suggests the need for disease-modifying therapy rather than supportive care alone?

a
Mild acrocyanosis with hemoglobin 12 g/dL
Mild symptoms without anemia often require conservative management.
b
Incidental cold agglutinins without hemolysis
Incidental cold agglutinins do not require therapy.
c
Occasional cold sensitivity during winter
Seasonal cold sensitivity alone does not justify therapy.
d
Persistent symptomatic anemia with ongoing hemolysis
Persistent symptomatic hemolysis indicates active disease requiring treatment.

A patient treated with complement inhibition therapy experiences rapid improvement in hemoglobin but continues to have mild acrocyanosis.

Which explanation best accounts for this observation?

a
Complement inhibition does not affect IgM-mediated RBC agglutination
Complement inhibitors reduce hemolysis but do not prevent IgM-mediated agglutination in peripheral vessels. As anemia improves, patients may become more active and notice circulatory symptoms more clearly.
b
Complement inhibitors increase RBC destruction
Complement inhibitors reduce rather than increase hemolysis.
c
Complement inhibitors suppress erythropoiesis
Complement inhibitors do not suppress erythropoiesis.
d
Complement inhibitors eliminate IgM antibodies
Complement inhibitors do not eliminate antibody production.

Sort the following therapies according to their primary target.

Rituximab
B-cell depletion
C1 inhibition
Bendamustine–rituximab
Complement inhibition
Complement-targeted therapies
Clone-directed therapies

Match the treatment strategy with its mechanistic target.

Bendamustine–rituximab regimen
Rituximab therapy
Blood transfusion
Deeper and more durable suppression of antibody-producing clone
B-cell depletion with moderate response durability
Temporary correction of anemia
Correct! Sorry, Incorrect.

Closing Note

Therapy for cold agglutinin disease is guided by mechanism.

Complement inhibition targets the effector pathway responsible for hemolysis.

Clone-directed therapy targets the source of the pathogenic antibody.

In some patients, both levels of the disease process must be addressed sequentially or simultaneously to achieve optimal control.

Prev
 1 / 17 
Next